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Resumo 
 
 Os objetivos a atingir em 2020 no que respeita ao processo de investigação e 
desenvolvimento de medicamentos estão claramente focados na redução em termos temporais na 
investigação pré-clínica e clínica e na diminuição da taxa de atrito entre as novas moléculas. De 
forma a atingir estes objetivos, um novo conceito tem sido desenvolvido e aplicado a este complexo 
e moroso processo, este é a Farmacologia Quantitativa e de Sistemas. Além disso, esta abordagem 
inovadora pode ser crucial para o tratamento de determinados tipos de tumores cerebrais letais – 
Glioblastoma Multiforme (GBM) – que permanecem um desafio terapêutico, e por tanto, uma 
doença com um destino fatal para os doentes. Por estas razões, esta dissertação de mestrado 
apresenta uma especial relevância, tendo por objetivos avaliar o potencial impacto e importância 
biológica da variação de parâmetros farmacológicos, para além da potência, no contexto da 
resposta celular ao fármaco, pela avaliação da perturbação induzida em células do GBM por 
inibidores do PDK1 e pela realização de uma caracterização multiparamêtrica dose-resposta destas 
novas moléculas. 
 A presente dissertação assume em Portugal a vanguarda na área da Farmacologia 
Quantitativa e de Sistemas aplicada ao processo de investigação e desenvolvimento de 
medicamentos. Em última estância, esta dissertação poderá contribuir para uma melhor previsão 
dos fármacos durante este processo, significando assim possíveis vantagens para os utentes, 
indústrias farmacêuticas, institutos de investigação, governo e institutos superiores.    
 
 
 
 
 
Palavras-chave 
PDK1 | Glioblastoma Multiforme | Farmacologia Quantitativa e de Sistemas | Investigação e 
Desenvolvimento de Medicamentos 
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Abstract 
 
The target objectives for 2020 regarding the drug discovery & development process are 
clearly focused on the reduction of the years of both preclinical and clinical research and decrease 
drug attrition rate. With a view to achieve this goal, a novel concept can be applied to this complex 
and time-consuming process – the Quantitative and Systems Pharmacology. In addition, this 
innovative approach can be critical for the treatment of a lethal type of primary brain tumour – 
Glioblastoma Multiforme (GBM) – which remains therapeutically challenging, therefore a disease 
with a clear dramatic fatal destination for patients. For these reasons, the present MSc thesis 
project has a special relevance by aiming to evaluate the potential impact and biological importance 
of variation in pharmacological parameters other than potency, in the context of cellular drug 
response, by measure the induced perturbations in GBM cells by PDK1 inhibitors and performing a 
multiparametric characterization dose-response of these drugs. 
This project assume in Portugal the vanguard on the area of Systems Pharmacology applied 
to drug discovery & development process. Ultimately, it will hopefully contribute to a better 
prediction of specific drugs, which means possible advantages for patients, pharmaceutical 
companies, research institutes, governments and academia. 
 
 
 
 
 
 
Keywords 
PDK1 | Glioblastoma Multiforme | Quantitative & Systems Pharmacology | Drug Discovery & 
Development 
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Introduction 
Drug Discovery & Development 
 
Nowadays and regarding the actual world economic conjuncture, on the science 
community the inefficiencies of the drug discovery and development process are a fashionable 
subject (Antman et al., 2012; Csermely et al., 2013). As we look back, we can see that this process 
has faced multiple paradigm shifts since its beginning, which dates back to the early days of human 
civilization (Chandra, 2009; Ji et al., 2009). Back there, drugs were much more than science, they 
were also associated with religious and spiritual healing. Those medicines were derived mainly from 
natural products, such as plants and supplemented by animal materials and minerals. Its discovery 
was probably done by combination of trial and error experimentation, observing the human and 
animal reactions. Just in the late 1800s, the drug discovery and development started to follow 
scientific techniques. This approach increased after the World War I, with the born of the modern 
pharmaceutical industry, rising and establishing the scientific principles of this complex process (Ji 
et al., 2009; Ng, 2008). In spite of this huge step on the modern pharmaceutical industry, the science 
behind the research and development (R&D) process has been changing, and the early process 
entirely focused on serendipity or systematic screening (Figure 1A) has been replaced by other 
process models, such as the ligand-centric approach (Figure 1B), and lately the target-centric 
approach (Figure 1C) (Chandra, 2009). 
In the last decades, within critical discoveries in science and technology, powerful tools to 
identify and optimize potential drug candidates were developed, however, the R&D productivity 
remains one of the biggest challenges (Brown at al., 2003; Abou-Gharbia et al., 2014). Analysing 
the concept of R&D productivity can be a complex task, but it can be simplified by considering the 
following two dimensions: efficiency and effectiveness. When we talk about efficiency of R&D, it 
means the ability to translate inputs – ideas, investment and effort – into defined outputs, such as 
milestones that represent resolved uncertainties (Swinney et al., 2011). This parameter has been 
highly discussed by financial markets that highlight fundamental inefficiencies in the current 
business model. And so, there is an urge for the industry to reduce costs and increase the efficiency 
of R&D (Williams, 2011). On the other hand, effectiveness of the process can be considered as the 
ability to produce outputs with certain intended and desired qualities (Swinney et al., 2011). In 
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order to achieve the required qualities of outputs, the European Medicines Agency (EMA), the Food 
and Drug Administration, (FDA), and other regulatory entities have assumed that it is critical the 
development of the regulatory science through this process, and so, increase the effectiveness of 
R&D (Gispen-de Wied et al., 2013).  
 
 
 
 
 
Figure 1 - Scientific background shifts for the drug discovery process. A) In the early days, the process started 
from the disease to drug treated as a ‘black box’ - serendipity or systematic screening. B) The ligand-centric 
approach with focus on medicinal chemistry. C) The subsequent shift to target focus called target-centric 
approach. Figure adapted from Chandra, 2009. 
Master of Pharmacy – Specialization in Applied Pharmacotherapy 
  
  
3 
 
 
Challenges  
 
In spite of the innovative developments during the last decades and the huge investments 
made, the R&D process is still largely inefficient, thus raising expressions such as “valley of death” 
& “curse of attrition” in the science community to express the drug failures during this process 
(Abou-Gharbia et al., 2014; Brown et al., 2003). Table 1 comprises a relatively high percentage of 
failure (29.9 %) for projects in the preliminary stage of discovery than projects achieving the later 
stages of the process. This proportion decreases to around 14 % in phase I and II of clinical trials. As 
well, around 10 % of the projects that are in phase 3 clinical trials fail to be launched in the market 
(Barrenho et al., 2013). Even for the drugs that pass these “valleys”, the understanding of their 
mechanism is lacking, and this fact is exacerbated by the gap on the respective representative 
disease models. Therefore, both therapeutic and side effect are poorly predictable (Zhao et al., 
2012; Hoeng et al., 2013). 
 
Table 1 – Descriptive statistics across the years between 1980 – 2012 for failures and successes in R&D, 
duration of the projects, competition, alliances and market size proxies. 
Reference: Barrenho et al., 2013 
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The high drug attrition rates – percentage of new molecules that start in one of the clinical 
evaluation phases and that fail to succeed on that phase (Moreira, 2014) – are the biggest challenge 
for R&D model, and understanding it is a key to better understand pharmaceutical industry 
performance, the magnitude of the long-term investments involved in R&D, and improving 
investment activity in the future (Barrenho et al., 2013; Csermely et al., 2013). In order to analyse 
the success of drugs during this process, there is reported two different types of metrics of success: 
‘Phase Success’ and ‘Likelihood of Approval’ (LOA). The first metric, ‘Phase Success’, is calculated as 
the number of drugs that moved from one phase to the next phase divided by the sum of the 
number of drugs that progressed to the next phase and the number of drugs that were suspended. 
The n value associated with the Phase Success represents the number of drugs that have advanced 
plus the number of drugs that have been suspended, labelled as transitions. The LOA denotes the 
probability of reaching approval from the current phase, being expressed in percentage. It is 
calculated as the product of each Phase Success probability leading to approval. The n value 
associated with LOA is the sum of the n values for each Phase Success included in the LOA 
calculation (Hay et al., 2014). 
Still on the side of the business model of R&D, additional challenges are related with key 
patents expiration, the increase of generic competition and the increasingly constrained healthcare 
budgets (Williams, 2011). These business concerns are strictly related with the scientific side of the 
question, since payers will look increasingly to only reimburse medicines that show a clear 
improvement in patient outcomes relative to existing therapies in defined patient populations, and 
so, there are some factors that might be critical to analyse and improve in this context: 
 Poor target quality, known as “druggability-trap” (Csermely et al., 2013); 
 Chemical leads are often discovered to have unwanted side-effects and/or be toxic 
at later development phases (Csermely et al., 2013); 
 Underestimation of the complexity of cells, organisms and human disease 
(Csermely et al., 2013); 
 Lack of mechanistic understanding of how drugs interactions at the molecular level 
manifest themselves as alterations in tissue/organ-level function (Zhao et al., 
2012); 
 The knowledge gained to assess other related drugs, or to develop new drugs is not 
used (Baird, 2012);   
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 Cellular and tissue/organ-level systems are treated as black boxes (Zhao at al., 
2012); 
 Patient-to-patient variability in drug response (Fallahi-Sichani et al., 2013); 
 Inability to predict adverse events when the drug is brought to market and used by 
the population at large (Zhao et al., 2012); 
 The more limited phenotypic screening in recent years (Swinney et al., 2011); 
 Data unreliable (Csermely et al., 2013). 
 
Oncologic Drug Discovery & Development Challenges 
 
In oncology, the R&D seems to be even more complex as the success rate of drug candidates 
is abysmally lower when compared with the other areas of healthcare. On that field, the success 
rates for drugs entering clinical development range from 3 to 8 % and less than 5% will be on the 
pharmacy shelf (Williams, 2011; Bhattacharjee, 2012). 
According to the analysis of discontinued drugs in oncology reports shown elsewhere 
(Williams, 2011; Williams, 2013a; Williams, 2013b), from 2006 to 2012 there is an upwards trend in 
the number of development terminations over the years, with no clear pattern, in 2010/11, to 
either the type of molecules terminated, with both small molecules and biological represented, or 
the biological axes targeted. However, the failure trend in 2012 benefited the biological therapeutic 
approaches (Table 2). Particularly noteworthy was the increase in Phase I terminations (Table 3) 
and the increase in discontinuous for strategic, including financial, reasons (Table 4). And so, the 
analysis of drugs discontinued from the global oncology pipeline in 2012 reflects similar trends to 
those reported for 2011 cohort.  
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Table 2 – Evolution trend on the type of molecules terminated from 2011 to 2012. 
2011 2012 
20 Small molecules 19 Small molecules 
13 Antibodies 8 Antibodies 
2 DNA-based therapeutics 1 Antisense oligonucleotide 
2 Non-antibody proteins 1 Cyclic Peptide 
 
 
Table 3 – Discontinued drugs by phase in 2006, 2007, 2008, 2010, 2011 and 2012.  
Year Phase I Phase II Phase III Total I-III 
2006 8 5 2 15 
2007 9 10 4 23 
2008 12 5 6 23 
2010 11 12 5 28 
2011 23 9 5 37 
2012 13 9 7 29 
 
 
Table 4 – Reasons for discontinued development of oncology drugs candidates in 2006, 
2007, 2008, 2010, 2011 and 2012.   
 
Year 
Reasons  
Total Unspecified Strategic Efficacy Toxicity PK Accrual 
2006 3 2 8 2 0 0 15 
2007 10 2 9 1 1 0 23 
2008 8 4 3 6 0 2 23 
2010 8 9 6 4 1 0 28 
2011 8 20 5 1 3 0 37 
2012 10 7 11 0 1 0 29 
 
 
Reference: Williams, 2013a; Williams, 2013b 
Reference: Williams, 2013b 
PK – Pharmacokinetics. Reference: Williams, 2013b 
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In addition to the challenges shown above, the lack of resources, wrong incentives, 
aggressive pricing strategies or adverse regulatory environments, no consideration of tumour 
microenvironment, cross-talk and negative feedback loops, development of resistance, exposure 
time, drug delivery or the choice of preclinical models must be considered. Much remains to be 
done in terms of increasing the efficiency of drug development, although new and more effective 
medicines are being approved for the treatment of cancer. Some of these drugs have made 
improvements in overall survival for all patients with a given condition, whereas others have only 
show benefit in smaller groups of patients with known molecular aberrations (Moreno et al., 2013).  
 
Innovation on the Drug Discovery & Development Process 
 
Dramatic changes to the scientific and business environments have made it impossible for 
pharmaceutical and biotech companies to continue operating as they have over the past 30 years 
(Csermely et al., 2013). Also, there is currently impossible to predict precisely the effects of a 
particular candidate drug in humans, making initially promising drugs lack efficacy or to have 
unsupportable levels of toxicity-typically at a late stage of a clinical trials, costing years of effort and 
up to $1 billion (Leo, 2011).  
To overcome these limitations, efforts and innovative approaches have been developed. 
One of them, which has been already reported as reaping benefit in terms of new, effective 
therapies seems to be the collaboration among academics, industry, regulators, government and 
not-for-profit organisations (Williams, 2013b). This has led to creation of large open-access 
databases of chemicals and associated bioactivity data, providing fantastic opportunities for 
computational research to contribute to a systemic understanding of drug-perturbed molecular and 
physiological processes, hopefully, leading to more rational drug discovery (Iskar et al., 2012).  The 
integration of computational systems approach for drug target discovery with high-throughput 
screening technologies – covering gene expression, proteomics, metabolomics or cellular 
phenotypes – will contribute in a wide extent to elucidate a drug’s general mechanism of action 
(MoA) on a biological system, and so, shortcut many aspects by generating hypotheses early on the 
process. Just by curiosity, the large-scale profile-based comparison of drug treatments were 
pioneered by the Connectivity Map (CMap) project (Iskar et al., 2012). Other integrations 
approaches have been developed, which is the case of the idea of ‘reversing disease profiles’, in 
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which diseases are characterized by disruptions of processes and networks at the cellular level, 
integrating profiles of altered gene expression, metabolite concentrations, and other. Also the 
incorporation of drug-drug similarity measures, side-effect profiles, properties of the drugs’ targets, 
disease-disease similarity, toxicity phenotypes, compound’s mechanism-based toxicity, 
characterize drug-induced organ and organism failures will be in the future part of the routine of 
the novel drug discovery and development process (Figure 2) and integrating modeling by 
computational systems approach is expected in a long run to be critical on this process (Figure 3) 
(Chandra, 2009; Iskar et al., 2012; PwC, 2011). 
 
 
 
Figure 2 – Drug discovery and development models. Evolution of the drug discovery processes has resulted in 
changing the discovery pipeline. A) ‘black-box’ model (red). B) Ligand-centric approach (Blue). C) Target-centric 
approach (cyan). D) Newly emerging shift to systems level focus (green). Various steps of the pipeline(s) as well 
the broad techniques that are required and the issues that they can address are also indicated in the figure. 
Reference: Chandra, 2009  
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Figure 3 – What the drug discovery process might look like with a fully developed computational systems 
approach – “Virtual Man”. Reference: PwC, 2011 
 
Nowadays, so far, some different metric approaches have been well established with the 
aim to improve the survival of development candidates and increase the speed at which these 
candidates are identified (Wager et al., 2010). These approaches are called ‘Target Product Profiles’, 
which are typically defined based on the existing body of knowledge and experience of 
development of orally dosed drugs, focusing the analysis of simple drug-like properties for known 
drugs, such as molecular weight (MW), lipophilicity (log P or log D), polar surface area (PSA), counts 
of hydrogen-bond acceptors (HBA), hydrogen-bond donors (HBD), aromatic rings (AROM) and 
rotatable bonds (ROTB). Some existing profiles based on different criteria are defined below (Yusof 
et al., 2014; Ritchie et al., 2014; Wager et al., 2010): 
 Lipinski’s Rule of Five; 
 3/75 concept introduced by Pfizer; 
 Patient Rule Induction Method (PRIM); 
 Central Nervous System Multiparameter Optimisation (CNS MPO) Algorithm; 
 Drug-likeness Score. 
For this project, drug-likeness score assumes a special importance regarding its previous 
application to the compounds provided by the Department of Pharmacy of the University of Pisa 
(Italy). Therefore, this profile aims to identify virtual or real molecules that fall into what is 
considered to be a drug-like chemical space, based on the calculated physicochemical properties of 
marketed oral drugs (quantitative estimate of drug-likeness, QED) and published human data, high-
scoring and low-scoring drugs, from 0 (all properties are completely undesirable) to 1 (all properties 
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are ideal). This calculation uses eight important properties, namely: MW, octanol-water partition 
coefficient (ALOGP), HBD, HBA, PSA, ROTB, AROM and number of structural alerts (ALERTS) (Ritchie 
et al., 2014; Yusof et al., 2014). This approach seems to be attractive as it integrates several 
important molecular properties and provides a continuous scale against which structures can be 
compared, where compounds can still achieve reasonable scores even if one or two properties are 
unfavourable because the others are close to ideal. Also, it solves the issues arising from the use of 
hard cut-off thresholds for physicochemical properties (Ritchie et al., 2014). 
Recently, the Harvard Medical School aiming to transform the drug discovery process 
launched an ‘Initiative in Systems Pharmacology’, which is a comprehensive strategy convening 
biologist, chemists, pharmacologists, physicists, computer scientist and clinicians to explore 
together how drugs work in complex systems, and so, transforming therapeutics. There are two 
broad goals of this initiative: significantly increase the knowledge of human disease mechanisms, 
the nature of heterogeneity of disease expression in different individuals, and how therapeutics act 
in human system; the other – based in this knowledge, trying to provide more effective translation 
of ideas to patients, by improving the quality of drug candidates as they enter clinical testing and 
regulatory approval process, aiming to increase the number of efficacious diagnostics and therapies 
reaching patients (Leo, 2011).   
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Quantitative & Systems Pharmacology 
 
What is it? 
 
As defined by the Quantitative and Systems Pharmacology (QSP) White Paper (Sorger et al., 
2011), QSP is an emerging discipline, which focus on identifying and validating drug targets, 
understanding existing therapeutics and discovering new ones. Its goal is to understand, in a 
precise, predictive manner, how drugs modulate cellular networks in space and time, moreover, 
how they impact human pathophysiology.  
The aim of this discipline is to develop formal mathematical and computational models that 
incorporate data at several temporal and spatial scales (Sorger et al., 2011; Iskar et al., 2012). The 
focus of these models will be on the interactions among multiple elements – biomolecules, cells, 
tissues and others – promoting the understanding and prediction of safety/efficacy profile (Agoram 
et al., 2011). Creation of multi-scale models that ultimately span knowledge of molecules, cells, 
tissues and patients will be particularly critical for preclinical and clinical research teams evaluating 
target selection and testing therapeutic proof of concept (Geerts et al., 2013; Sorger et al., 2011).  
QSP draws on several existing disciplines, including classic pharmacology, chemical biology, 
biochemistry and structural biology, molecular genetics and genomics, pathology, applied 
mathematics, and medicine, and has an intrinsic and extensive experimental component that 
incorporates approaches from tissue and organ physiology, pharmacology and cell biology as well 
as bioinformatics and “-omics” approaches, for example genomics, proteomics and metabolomics 
analysis (Sorger et al., 2011; Zhao et al., 2012). QSP will accelerate drug discovery and development 
by helping to identify and validate targets (and druggable) networks, uncover drug-response 
biomarkers, design better drugs and drug combinations, select appropriate doses and dosage 
regimens and identify those patients most likely to respond to new therapeutic agents and 
combinations. It will therefore become a core discipline of translational medicine, which aims to 
convert the understanding of biological mechanisms into effective ways of treating and preventing 
diseases (Cucurull-Sanchez et al., 2012; Baird, 2012; Sorger et al., 2011). 
 
Master of Pharmacy – Specialization in Applied Pharmacotherapy 
  
  
12 
 
 
Parameterising perturbagen dose-response relationships  
 
In order to assess the prediction of the drug response, and so, better characterize the drug 
and the whole system, other metrics than variation in potency (half-maximum inhibitory 
concentration – IC50) must be systematically measurement and integrated with other scientific 
technologies (Fallahi-Sichani et al., 2013). 
The focus to date on potency ignores the potential impact and biological importance of 
variation in other parameters, such as the (Fallahi-Sichani et al., 2013; Heiser et al., 2011): 
 Steepness of the dose-response curve, called Hill Slop (HS); 
 Maximum Effect (E0 or Emax); 
 Minimum Effect (Einf); 
 Area under the dose-response curve (AUC); 
 Concentration needed for growth inhibition by 50% (GI50); 
 Total Growth Inhibition (TGI); 
 Concentration at half-maximal effect (EC50). 
During the development of a novel compound, reducing IC50 is certainly an important goal, 
but when the aim is to understand variability in patient responses to an existing drug, it is likely to 
be more informative to focus on E0 and HS. Furthermore, different dose-response parameters 
encode distinct information (Fallahi-Sichani et al., 2013):    
 E0, IC50, AUC are parameters for simplicity; 
 EC50, IC50 are classic measures of drug potency; 
 E0, Einf are measures of drug efficacy; 
 AUC combines potency and efficacy of a drug into a single parameter. 
Some of the parameters mentioned above are reported to vary systemically with cell line 
and others with drug. For example, for cell-cycle inhibitors, E0 often but not always correlate with 
cell proliferation rate. In the case of drugs targeting protein kinase B/phosphtaidylionositol-3-
kinase/mammalian target of rapamycin (Akt/PI3K/mTOR) pathway, dose-response curves are 
reported to be unusually shallow. Also, HS and E0 shown to be frequently uncorrelated with each 
other or with GI50, but the parameters varied in a consistent way with drug class. On that line, it 
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was shown so far that HS was particularly high for drugs such as proteasome and histone 
deacetylase (HDAC) inhibitors, whereas inhibitors of the Akt/PI3K/mTOR pathway had low and 
variable HS, special drugs as PP242, temsirolimus, everolimus and rapamycin. In many cases, 
classical pharmacology has no ready explanation for this phenomenon of variation in dose-response 
parameters. Association with drug class or target is confounded by polypharmacology, which 
almost certainly affects the shape of dose-response curves at high drug concentrations, particularly 
with phenotypic measures of response (Fallahi-Sichani et al., 2013).  
 
Systems Pharmacology: Glioblastoma Multiforme 
  
Epidemiology 
 
Glioblastoma Multiforme (GBM) is the most common intrinsic primary brain tumour in 
adults, and represents over 80% of diffuse gliomas (Toda, 2013). The age-adjusted rate for 
glioblastoma is 3.19/100 000, according to the last Central Brain Tumour Registry of the United 
Stated of America (CBTRUS) statistical report. It is evident that glioblastoma increases with age and 
incidence is 75-84 years old, being more common in white males. When it comes to children, GBM 
accounts approximating 3 % of all primary brain and Central Nervous System (CNS) tumours. The 5 
year survival rate is approximately 12 % in children and <5% in adults (Olar et al., 2014). 
 
Definitions & Histopathological Diagnosis 
 
According to the World Health Organisation (WHO) Classification of Tumours of the CNS 
(4th edition, 2007), GBM is by far the most aggressive diffuse glioma of the astrocytic lineage. 
Others malignant diffuse gliomas are additionally comprised of oligodendroglia, and mixed 
oligoastrocytic neoplasms based solely on morphology and are further subdivided by tumour grade 
based on additional histologic features present in the tumour (Dunn et al., 2012).   GBM 
corresponds to grade IV and it is most common in the cerebral hemispheres, but it may involve any 
neuroanatomical level or structure (Olar et al., 2014). 
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Histologically, glioblastoma is composed of pleomorphic cells, mitotic activity, intravascular 
microthrombi, necrosis with or without cellular pseudopalisading and/or microvascular 
proliferation (MVP) (Figure 4). Either one of the latter two features are the sine qua non criteria for 
diagnosis. This aggressive tumour encloses under its umbrella multiple distinct patterns ( small cell, 
giant cell, gliosarcoma, etc.) (Olar et al., 2014). 
 
 
The WHO classification is based on subjective criteria and is imperfect in predicting patient 
outcome. Tumours may appear virtually identical by histology, yet still have very different 
outcomes. Beyond their histological criteria, progress in molecular techniques has allowed the 
identification of a number of markers and genetic profiles that can characterize gliomas (Hofer et 
al., 2014). 
Glioblastoma may be divided into two identical morphological subtypes, based on the 
presence or absence of a precursor lesion. Primary glioblastoma is the most common type (~90%); 
it arises de novo, without evidence of a precursor lesion, and is common in older adults (> 50 years). 
Secondary glioblastoma represents progression from a pre-existent, lower-grade astrocytoma 
(WHO grades II or III) (Dunn et al., 2012). The time to progression from diffuse astrocytoma (WHO 
grade II) to glioblastoma is longer ( ~ 5 years) than the time to progression from anaplastic 
astrocytoma (WHO grade III), which is about 2 years. However, this is not a straight process (Olar 
et al., 2014). 
 
Figure 4 – Histopathology of glioblastoma. Proliferating atypical cells with mitotic activity, necrosis 
with pseudopalisading (left) and microvascular proliferation (right). Reference: Olar et al., 2014 
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Cellular and Molecular Biology Heterogeneity  
 
Although morphologically identical, different glioblastoma tumours has been shown 
different clinical behaviours, and so, different clinical outcomes (Olar et al., 2014). Also, so far, it is 
well recognized that GBM shows high complex heterogeneous cellular, molecular, 
microenvironmental characteristics, which might partially explain the variety of clinical responses 
(Olar et al., 2014; Hofer et al., 2014; Dunn et al., 2012). Therefore, it is highly important to identify 
biomarkers able to predict individual prognosis and to develop specifically directed therapies 
(Denysenko et al., 2014).  
Recently, there is increasing evidence that tumour bulk mass contain subpopulations of 
cells, such as glioma-initiating cells (GICs) and glioma stem cells (GSCs), which renders the so-called 
‘novel strategies’ an old fashioned procedure (Persano et al., 2011; Sampetrean et al., 2013). When 
it comes to the glioma cells of origin – their cellular origin that give rise to the initial tumour – 
continues to be a source of debate (Table 5) (Sampetrean et al., 2013; Dunn et al., 2012). There is 
reported that neural stem cells (NSCs) or oligodendrocyte precursor cells (OPCs) might be putative 
glioma cells of origin (Figure 5) (Sampetrean et al., 2013; Clarke et al., 2013).  
 
 
Table 5 – Similarities and differences among GSCs, glioma cells of origin, and GICs. 
Reference: Sampetrean et al., 2013 
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At the moment, there is absent unequivocal biomarkers to well characterize this newly 
discovered type of cells – GICs – making it as a remaining working hypothesis to be adjusted and 
validated through further research. Hopefully, a better characterization of GICs, and through them 
the glioma cells of origin, will increase the understanding of the initial steps of gliomagenesis and 
could lead to early detection and even prevention of this intractable disease (Sampetrean et al., 
2013).    
Figure 5 – Possible cells of origin of glioma. Studies in mouse models have shown that various cell types can 
give rise to glioma. Neural stem cells (NSCs) give rise to other Neural Stem Cells, Astrocytes, Astrocyte-like 
cells, and neurons. It is demonstrated that NSCs give rise to OPCs, which can give rise to glioma (Liu et al., 
2011). Others shown that astrocytes and neurons can give rise to glioma (Marumoto, Singer, Ellisman, & 
Verma, 2013). Also, astrocytes can give rise to glioma after platelet-derived growth factor (PDGF) 
overexpression and lnk4a, and ARF deletion as said somewhere (Hambardzumyan, Cheng, Haeno, Holland, & 
Michor, 2011). As well, overexpression of a mutagenic Sleeping Beauty (SB) transposon (T2/Onc2) along with 
a dominant negative p53 in astrocyte like cells can give rise to glioma (Koso et al., 2012). Additionally, it is 
reported that NSCs could give rise to glioma after Nf1, p53, and Pten deletion (Chen, McKay, & Parada, 2012). 
Neural stem cells can give to proneural, mesenchymal, and neural cell lineages.  Reference: Clarke et al., 2013 
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The cellular microenvironment also plays a critical role in the regulation of cells in GBM. 
The heterogeneous cell populations do not only catch external signals from the environment but 
also respond to the latter in order to take advantage of it (Schonberg et al., 2013). Therefore, there 
is reported and well accepted the following tumour-associated parenchyma cells interact with GBM 
cells, controlling the course of the pathology (Goffart et al., 2013):   
 Involvement of Microglia; 
 Involvement of the Immune System; 
 Involvement of Neural Progenitors; 
 Involvement of the Vascular Niche. 
For instance, GSCs often reside and thrive in perivascular and hypoxic (region of irregular 
blood flow that experience fluctuating abnormal hypoxic oxygen tension levels, ranging from less 
than 1-5%) niches (Figure 6), which are anatomical and functional locations. 
Figure 6 – GSCs microenvironment. GSCs often reside and thrive in perivascular and hypoxic niches 
where growth factors and cytokines promote their maintenance. In turn, GSCs up-regulate the 
expression, activation and secretion of a number of niche-dependent signaling molecules and 
transcription factors involved in pathways such as angiogenesis, proliferation, migration, hypoxia 
response, etc. GSCs interact with other tumour cells and have the potential to differentiate into other 
cell types including endothelial cells and pericytes. Reference: Schonberg et al., 2013 
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The morphological heterogeneity that prompted the original description of high-grade 
glioma as glioblastoma multiforme has also extended to the molecular level and these molecular 
alterations are extremely complex (Dunn et al., 2012). Based on genomic profiling of hundreds of 
human samples, four subtypes of GBM have been proposed and these subgroups might develop 
from different cells of origin (Clarke et al., 2013): 
 Proneural GBMs – altered expression of platelet-derived growth factor receptor, 
alpha polypeptide (PDGFRA); isocitrate dehydrogenase 1 (IDH1); tumour protein 
p53 (TP53) mutation; loss of heterozygosity (LOH) along with phosphatase and 
tensin homolog (PTEN) mutation; and cyclin-dependent kinase inhibitor 2A 
(CDKN2A) loss; 
 Mesenchymal GBMs – deletion of neurofibromin 1 (NF1), mutation of TP53 and 
PTEN, and loss of CDKN2A; 
 Classical GBMs – typified by epidermal growth factor receptor (EGFR) amplification 
and lack of PTEN, and CDKN2A; 
 Neural GBMs – show a strong expression of neuron markers and genes associated 
with neuron projection and axon and synaptic transmissions.  
Epigenetic alterations has been increasingly debated and studied in GBM. Some regulator 
agents on that matter are micro-ribonucleic acid – miRNA – approximately 21-nucleotides in length, 
single stranded endogenous non-coding RNAs (ncRNAs) that post-transcriptionally modulate gene 
expression and by that regulate a wide array of biological processes including differentiation, cell 
cycle, cell proliferation, apoptosis and angiogenesis; competitive endogenous RNAs – ceRNAs – 
control the amount of each miRNA species; long non-coding RNAs – lncRNAs – control global gene 
repression. Also, epigenetic enzymes, which are controlled by these RNAs, might play a critical role 
as GBM drivers (Clarke et al., 2013). 
 
Network Analysis   
 
A network is defined as a series of entities connected to one another on the basis of a 
defined criterion (Zhao et al., 2012). The entities are named network nodes or vertices or network 
elements, which represent different types of objects such as genes, proteins, drugs, and disease. 
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On these networks there are edges, which are often called interactions, connections, or links. In 
terms of local topology, there can be described hubs, motifs and graphlets. A hub is a node having 
a much higher number of neighbours than average. Usually, hubs are attractive as drug targets. In 
the case of network motifs, they are circuits of 3 to 6 nodes in directed networks that are highly 
overrepresented as compared to randomized networks. Lastly, graphlets are similar to motifs but 
are defined as undirected networks (Csermely et al., 2013). 
Recently, there was created a functional interaction (FI) network to study GBM by 
developing a human-curated map of the molecular pathways involved in GBM (Figure 7) (Wu et al., 
2010). 
Figure 7 – Overlay of predicted functional interactions onto a human curated GBM pathway. Many genes can 
interact with multiple pathways genes. In this diagram, only genes interacting with one pathway gene are shown 
to minimize diagram clutter. Newly added genes are colored in light blue, while original genes are colored in grey. 
Newly added FIs are in blue, while original interactions are in other colors. FIs extracted from pathways are shown 
as solid lines, while those predicted based on Naïve Bayes classifier (NBC) are shown as dashed lines. Extracted FIs 
involved in activation, expression regulation, or catalysis are shown with an arrowhead on the end of the end of 
the line, while FIs involved in inhibition are shown with a ‘T’ bar. Reference: Wu et al., 2010 
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PDK1 Structure & Pathway 
 
The 3-phosphoinositide-dependent protein kinase-1 (PDK1) is a serine/threonine kinase, 
discovered over a decade ago. Its structure consists of an N-terminal kinase domain (amino acids 
71-359) and a carboxyl-terminal (C-terminal) pleckstrin homology (PH) domain (amino acids 459-
550), which binds PtdIns(3,4,5)P3 and PtdIns(3,4)P2 (Figure 8) (Nesi, 2011a). 
Identification of the PH domain as a specialized lipid-binding module has been an important 
clue in understanding the mechanism by which membrane-bound lipids convey signals to the 
cytoplasm. Deletion of the PH domain prevents PDK1 recruitment to the plasma membrane and 
affects the activation and membrane localization of Akt. Binding of PDK1 to PtdIns(3,4,5)P3 induces 
a major conformational change that is likely required for the activation of substrates. However, 
PtdIns(3,4,5)P3 binding to the PH domain of PDK1 does not affect the activity of PDK1 directly (Nesi, 
2011a). 
Figure 8 – PDK1 feature view of Protein Data Bank (PDB) entries mapped to a UniProtKB sequence. Data in 
green originates from UniProtKB. Data in yellow originates from Pfam, by interacting with the HMMER3 web 
site. Data in grey has been calculated using BioJava. Protein disorder predictions are based on JRONN, a Java 
implementation of RONN: red – potentially disorderd region; blue – probably ordered region. Hydropathy has 
been calculated using a sliding window of 15 residues and summing up scores from standard hydrophobicity 
table: red – hydrophobic; blue – hydrophilic. Data in blue originates from PDB. Secstruct: Secondary structure 
projected from representative PDB entries onto the UniProt sequence. Data in red indicates combined ranges 
of Homology Models from SBKB and the Protein Models Portal. Reference: From Protein Data Bank (Rutgers, 
2014) 
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PDK1 belongs to the protein kinase superfamily, AGC protein kinase family, PDPK1 
subfamily, acting as a master upstream protein kinase, phosphorylating and activating a subgroup 
of the AGC family of protein kinases implicated in the control of cell growth, proliferation, survival 
and metabolism regulation (Nesi, 2011a; Sephton et al., 2009). The AGC group is named after three 
of its substituents: cyclic adenosine monophosphate (cAMP)-dependent (protein kinase A, PKA), 
cyclic guanosine monophosphate (cGMP)-dependent protein kinase (PKG) and protein kinase C 
(PKC). Members of this group preferentially phosphorylate serine/threonine residues close to 
arginine and lysine, the basic residues. Like all members of this family, the catalytic core of PDK1 
possess (Figure 9) an amino-terminal (N-terminal) lobe that consists mainly of a β-sheet and a 
predominantly α-helical C-terminal lobe, whereas, unlike other AGC kinases, PDK1 possesses an HM 
pocket in the small lobe of its catalytic motif. The αC-helix (residues 124-136), located in the small 
lobe of the kinase domain, is a key regulatory domain because it links a substrate interacting site 
termed the hydrophobic motif (HM) pocket with Ser-241 in the activation loop. The HM pocket in 
the kinase domain of PDK1 has been termed the PIF pocket after the first discovery that the C 
terminus of PKC-related kinase-2, which contains an HM motif, interacts with the kinase domain of 
PDK1. Then, PDK1 interacting fragment (PIF) pocket act as a docking site, which enables the kinase 
to interact with some of its physiological substrates  (Biondi et al., 2002; Feldman et al., 2005).  
 
 
 
 
 
 
 
 
 
 
Phosphate-pocket 
PIF-pocket 
Ser-241 
Small lobe 
Large lobe 
Figure 9 – Overview of the PDK1 structure. Generated by Jmol Java 
Console. 
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Protein phosphorylation plays a key regulatory role in numerous facets of protein 
behaviour including localization, activity and intermolecular interactions and it is mediated by 
kinases and phosphatases. PDK1 show to be a constitutive active kinase that can use distinct 
mechanisms to phosphorylate different substrates within cells. Its targets include (Swiss-prot, 2013; 
Sephton et al., 2009): 
 Protein kinase B (PKB/AKT1, PKB/AKT2, PKB/AKT3); 
 p70 ribosomal protein S6 kinase beta-1 (RPS6KB1); 
 p90 ribosomal protein S6 kinase alpha-1 (RPS6KA1), p90 ribosomal protein S6 
kinase alpha-2 (RPS6KA2) and p90 ribosomal protein S6 kinase alpha-3 (RPS6KA3); 
 cAMP-dependent protein kinase (PRKACA); 
 Protein kinase C delta type (PRKCD) and Protein kinase C zeta type (PRKCZ); 
 Serum/glucocorticoid-inducible kinase 1 (SGK1), serum/glucocorticoid-inducible 
kinase 2 (SGK2) and serum/glucocorticoid-inducible kinase 3 (SGK3); 
 p21-activated kinase-1 (PAK1); 
 Serine/threonine-protein kinase N1 (PKN1) and Serine/threonine-protein kinase 
N2 (PKN2). 
In glioblastoma multiforme, PDK1 is directly or indirectly part of critical molecular pathways 
which regulate several growth factors and oncogenes (Krakstad et al., 2010; Mao et al., 2012): 
 Phosphtaidylionositol-3-kinase (PI3K)/PDK1/Akt pathway: one of the most critical 
and best characterized pathways in gliomas, being important in cell survival, 
migration and proliferation; 
 PI3K-mTOR crosstalk pathway: critical for proliferation and angiogenesis; 
 PTEN-Akt-mTOR signaling pathway: regulates normal cellular functions that can be 
crucial in tumorigenesis, including cellular proliferation, apoptosis, cell invasion, 
and mobility. 
Additionally as shown above, cytokines such as interleukin-6 (IL-6) have been reported to 
influence the PI3K/AKT signaling pathway (Guven-Maiorov et al., 2014). 
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Treatment Options 
 
In spite of the increased understanding of the complex processes underlying GBM 
development, this disease still has a dramatic prognosis that has not improved during the last two 
decades, therefore, a pathology with a clear fatal outcome for patients (Denysenko et al., 2014). 
Standard treatment upon initial diagnosis of GBM consists of maximal surgical resection, 
radiotherapy, and concomitant and adjuvant chemotherapy with temozolomide (TMZ) (Fialho et 
al., 2012).  In the case of patients older than 70 years less aggressive therapy is sometimes 
employed, through radiation or sole administration of temozolomide. For these patients, recent 
evidence suggests that temozolomide or hypofractional radiotherapy is associated with prolonged 
survival than treatment with standard fractioned radiotherapy. For patients over 60 years old, in 
turn, temozolomide therapy has been shown to lead to a longer survival than treatment with 
standard radiotherapy (Malmström et al., 2012). 
Average time to recurrence after standard therapy is presently 6.9 months for GBM 
patients. For recurrent tumours, surgery is appropriate in selected patients, and various 
radiotherapeutic, chemotherapeutic, biologic, or experimental therapies are also employed (Stupp 
et al., 2005; Chamberlain et al., n.d.).  
The radiation therapy for GBM patients involves focal, fractioned external beam therapy 
while current drugs are alkylating agents such as temozolomide, often in combination with 
inhibitors of growth factors that promote tumour growth such as the inhibitor (erlotinib) of 
epidermal growth factor receptor (EGFR)  (Fialho et al., 2012). Dose response relationships for GBM 
demonstrate that a radiation dose of less than 4500cGy results in a median survival of 13 weeks 
compared with a median survival of 42 weeks with a dose of 6000 cGy. This is usually administered 
in a therapeutic scheme of 5 days per week in doses of 1.8-2.0 Gy (Bruce et al., 2014b). 
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The optimal chemotherapeutic regimen for GBM is not yet defined, however, there are 
some therapeutic options, even not being specific to treat GBM (Bruce et al., 2014a; Bruce et al., 
2014b; Mao et al., 2012): 
 Temozolomide (Temodar): an oral alkylating and chemotherapeutic agent, first 
used to treat primary brain tumours in 1993. It alkylates or methylates DNA, 
causing cancer cells to die. O-6-methylguanine-DNA methyltransferase (MGMT) or 
O-6-alkylguanine-DNA alkyltransferase can diminish the effect of TMZ by repairing 
the DNA damage. Also, TMZ has been combined with other inhibitors, in many 
phase I and II clinical trials, such as EGFR inhibitor, erlotinib, and radiotherapy and 
shown improvement on patient survival; 
 Carmustine (BiCNU): Alkylates and cross-links DNA strands, inhibiting cell 
proliferation; 
 Cisplatin (Platinol): DNA damaging agent (DNA crosslinks and denaturation of 
double helix), inhibits protein synthesis and, thus, cell proliferation. 
 Erlotinib (Tarceva): a human epidermal growth factor receptor type1/epidermal 
growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor. EGFRs are 
overexpressed in multiple GBM cases and play a significant role in regulating other 
intracellular significant pathways that contribute to GBM pathogenesis, including 
mTOR/PI3K/Akt and Rat Sarcoma/mitogen-activated protein kinase (RAS/MAPK). 
 Gefitinib (Iressa): An aniliniquinazoline, which mechanism is not fully understood, 
but seems to inhibit tyrosine kinase intracellular phosphorylation associated with 
transmembrane cell surface receptors.  
Certain conditions related with this type of tumour require medical treatment. For seizures, 
the patient usually is started on levetiracetam (Keppra), phenytoin (Dilantin), or carbamazepine 
(Tegretol). Levetiracetam is often used because it lacks the effects on the P450 system seen with 
phenytoin and carbamazepine, which can interfere with antineoplastic therapy. Vasogenic cerebral 
edema is typically managed with corticosteroids (for example, dexamethasone), usually in 
combination with some form of antiulcer agent (for instance, famotidine, ranitidine). The American 
Academy of Neurology's practice parameters state that prophylactic antiepileptic drugs (AEDs) 
should not be administered routinely to patients with newly diagnosed brain tumours (standard) 
and should be discontinued in the first postoperative week in patients who have not experienced a 
seizure (Glantz et al., 2000). 
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Therapeutic Challenges 
 
In glioblastoma multiforme drug discovery, one of the biggest challenges is defining the 
cellular origin of GBM since it is difficult to develop a successful GBM treatment without first 
uncovering the responsible cell or cells types to eliminate, having in mind the complex 
heterogeneity of this specific cancer type (Clarke et al., 2013). Nevertheless, the tumour location in 
a region where it is beyond the reach of local control, and rapid, aggressive tumour relapse are 
further challenges related to tumour aspects to overcome. Other factors that frustrate therapeutic 
interventions are the physiologic barriers (blood brain barrier, blood-cerebrospinal fluid barrier and 
blood-tumour barrier), mechanisms of transport (for example, efflux) and physicochemical factors 
(for instance, log octanol-water partition coefficient (logPo/w), permeability-surface area product 
(PS) or permeability coefficient (PC)) (Misra et al., 2003). As well as, identifying epigenetic targets 
for GBM treatment and subsequently develop therapeutic strategies against GBM are further steps 
to overcome.  
In a time where the bio – and nanotechnology applied to medicines is growing 
exponentially, the development and design of novel approaches to promote an efficient, effective 
and safe drug delivery to the specific regions of the brain while planning therapeutic regimen and 
monitoring the responses to treatment would help to overcome some therapeutic limitations such 
as neurotoxicity, lack of specificity, poor drug accumulation in tumours and severe side effects 
(Caruso et al., 2011). 
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Aims of the Study 
 
This MSc study assume in Portugal the vanguard on the area of Quantitative & Systems 
Pharmacology applied to glioblastoma multiforme drug discovery & development.  
The main goal of the work is evaluate the induced drug perturbation in glioblastoma cancer 
cells through in vitro assays by performing a multiparametric characterization of the PDK1 inhibitors 
dose-response. Specifically it means: 
 Grow the U-87 MG Human Cell Line representative of the human glioblastoma 
multiforme; 
 Perform the cellular growth profile; 
 Parameterising multiparamentric perturbagen dose-response relationships for two 
newly synthetised PDK1 inhibitors (G51 and FC100). 
The results obtained and the efforts made, ultimately, might contribute to the development 
of tools to better predict the drug effects before it reach clinical trials, and so, improve the R&D 
process and possible clinical outcomes. These would means possible advantages for patients, as 
well as for pharmaceutical companies, research institutes, governments and academia. 
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Materials & Methods 
 
In this study, the effects of two PDK1 inhibitors were parameterised in a multiparametric 
dose-response relationship way on U-87MG Human glioblastoma astrocytoma cell line by fitting 
pharmacologic experimental methods to dedicated models. The detailed experimental procedures 
will be described on this section. 
 
Reagents 
 
Table 6 – List of the reagents used along the study. 
Reagent Supplier 
Aseptic Technique and Good Cell Culture Practice 
70% Ethanol Prepared on the laboratory 
70% Isopropanol Prepared on the laboratory 
Sodium Hypochlorite Random 
Preparation of Sample Solutions 
Phosphate Buffered Saline (PBS) 
powder, pH 7.4 in 1L sterile water 
Powder from Sigma-Aldrich Chemical S.L., 
Sintra, Portugal; Solution prepared on the 
laboratory 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Cell Culture 
Dulbecco’s Modified Eagle’s Medium – high 
glucose with 4500 mg/L glucose and L-
glutamine, without sodium bicarbonate, 
powder 
Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Penicillin-Streptomycin, liquid Invitrogen, Barcelona, Spain 
Fetal Bovine Serum (FBS) Invitrogen, Barcelona, Spain 
Sodium bicarbonate, powder Sigma-Aldrich Chemical S.L., Sintra, Portugal 
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Phosphate Buffered Saline (PBS) powder, pH 
7.4 in 1L sterile water 
Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Trypsin-EDTA Solution Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Trypan Blue Solution Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Sulforhodamine B (SRB) Colorimetric Assay 
Phosphate Buffered Saline (PBS) 
powder, pH 7.4 in 1L sterile water 
Powder from Sigma-Aldrich Chemical S.L., 
Sintra, Portugal; Solution prepared on the 
laboratory 
Methanol (MeOH) Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Sulforhodamine B Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Acetic acid José M. Vaz Pereira, Lisboa, Portugal 
Tris(hydroxymethyl)aminomethane or Tris 
National Diagnostic, Hessle Hull, United 
Kingdom 
Cell Lysis and Protein Extraction 
Dithiothreitol (DTT) Bio-Rad Laboratories, Amadora, Portugal 
Glycerol Sigma-Aldrich Chemical S.L., Sintra, Portugal 
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) 
Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Magnesium chloride (MgCl2) Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Sodium chloride (NaCl) Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Phenylmethanesulfonyl fluoride solution 
(PMSF) 
Sigma-Aldrich Chemical S.L., Sintra, Portugal 
Pepstatin A AppliChem, Germany 
Leupeptin hemisulfate AppliChem, Germany 
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Equipment 
 
Table 7 – List of the equipment used along the study. 
Equipment Supplier 
Aseptic Technique and Good Cell Culture Practice 
Personal protective equipment (sterile gloves, 
laboratory coat, safety visor, others) 
Various 
Microbiological Safety Cabinet class II 
Biowizard (BW)-100 
Kojair Tech Oy, Vilppula, Finland 
Preparation of Sample Solutions 
Vortex, IKA, MS2 Minishaker Deutschland, Germany 
Falcon 15 mL tubes Orange Scientific, Braine-l’Alleud, Belgium 
Filter Frilabo, Maia, Portugal 
Syringe Terumo Medical Corporation, Canada 
Cell Culture 
Microbiological Safety Cabinet class II 
Biowizard (BW)-100 
Kojair Tech Oy, Vilppula, Finland 
MCO-19A Incubator Sanyo Electric Co. Ltd., Japan 
NE1B-14 Water bath Clifton, England 
Olympus CKX41 Microscope with an Olympus 
DP20-5E Digital 
Olympus Optical Co. Ltd., Japan 
MPW-350R Centrifuge  MPW Medical Instruments, Poland 
Plates, Flasks, Eppendorfs & Falcon tubes Orange Scientific, Braine-l’Alleud, Belgium 
Sulforhodamine B (SRB) Colorimetric Assay 
Plates Orange Scientific, Braine-l’Alleud, Belgium 
Bio-Tek µQuant MQX200 
Spectrophotometer UV-VIS  
(Gen5 software) 
Bio-Tek, United States 
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Compounds & Stock Solutions 
 
The new PDK1 inhibitors used in this project (Table 8 and 9) – G51 and FC100 – were 
synthesised and kindly provided upon collaboration with Dr. Simona Rapposelli from the 
Department of Pharmacy of the University of Pisa, Italy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8 – Physicochemical properties of G51 compound. 
MW – Molecular weight; MF – Molecular formula. 
Purity clogP Drug like properties Melting point MW MF
169-171
459.50 
g.mol-1
C25H25N5O4
Structure
G51
± 0.4 % 0.8 -4.88
Table 9 – Physicochemical properties of FC100 compound. 
MW – Molecular weight; MF – Molecular formula. 
Purity clogP Drug like properties Melting point MW MF
C13H12N4O3S
FC100
Structure
± 0.4 % -0.25 2.72 205-207
304.32 
g.mol-1
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Two different stock solutions of these inhibitor were prepared and it can be visualized on 
the Figure 10.  
 
 
 
Figure 10 – Schematic representation of compound solutions preparation. Stock solutions 1 of PDK1 
inhibitors were made by dissolving each compound in 100% DMSO followed by sterile-filtration, and then, 
dilution with PBS, obtaining the stock solutions 2. Further dilutions were made from stock solutions 2 with 
PBS to obtain the required concentrations – ranging from 25 µM to 400 µM – in eppendorfs.  Remaining stock 
solutions 2 were stored at 4°C. Additional dilutions were made in complete cell culture medium to obtain the 
concentration required on the well (2.5 µM – 40 µM). 
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Cell Culture  
 
The U-87 MG human glioblastoma astrocytoma cell line was kindly offered by Professor 
Conceição Pedroso de Lima, from the Center for Neuroscience and Cell Biology of the University of 
Coimbra, Portugal. The cells were at the passage number 28, mycoplasma free and frozen on 
28.10.2013. 
 
Resuscitation of Frozen Cell Lines 
 
In order to maintain the viability of the cell culture and enable it to recover more quickly, it 
is vital to thaw cells correctly. Since some cryoprotectants, such as DMSO, are toxic above 4 °C, the 
cells were thawed quickly and diluted in culture medium to minimise the toxic effects. Followed by 
centrifugation (to remove the cryoprotectant), the supernatant was removed and the cells were re-
suspended in growth medium. Then, they were transferred to a 75 cm2 flask and incubated at 37 
°C, 5% carbon dioxide (CO2). Cells were examined microscopically (phase contrast) after 24 hours 
and the medium replaced.  
 
Cell Morphology & Cell Culture Conditions 
 
The U-87 MG cells have an epithelial-like morphology (Figure 11), therefore growing in 
adherent mode. 
 
 
 
 Figure 11 – U-87 MG cell line human glioblastoma 
astrocytoma. 100x total amplification, after 72h of seeding.  
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Cells were seeded at a 1.5 x 105 cells/mL (density) in 75 cm2, 150 cm2 or 175 cm2 culture 
flasks and they were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g/L 
glucose supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mol penicillin 
and 100 µg/mL streptomycin. They were grown at 37 °C under humidified atmosphere containing 
5% CO2. 
 
Subculture of Adherent Cell Lines 
 
U-87 MG cells were splitted when sub-confluent (70-80 %) as recommended on the cell line 
data sheet from Sigma-Aldrich. Cells were brought into suspension by using tripsinisation. Upon 
centrifugation at 1100 for 5 minutes, cells were counted in a haemocytometer, using the Trypan 
blue colorimetric exclusion assay and then seeded at 1.5 x 105 cells/mL density.  
 
Cell Quantification 
 
For the majority of manipulations using cell cultures, for example cryopreservation and 
subculture routines, it is necessary to quantify the number of cells prior to use. Also, by doing that, 
cells maintain optimum growth, as well as, it helps to standardise procedures using cell cultures. 
This in turn gives results with better reproducibility (ECACC, 2013).  
When required, cell quantification was performed after harvesting cells by tripsinisation as 
described above. Cells were re-suspended in a required volume of fresh culture medium and 20 µL 
were placed on an eppendorf with the same amount of Trypan blue dye (dilution factor 2).  This cell 
suspension was then placed onto a haemocytometer chamber. Cell count was the following step 
(Figure 12) and the calculation of cell density was achieved by following the equation (ECACC, 2013): 
 
𝑉𝑖𝑎𝑏𝑙𝑒 𝐶𝑒𝑙𝑙 𝐶𝑜𝑢𝑛𝑡 (𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝑖𝑙𝑙𝑖𝑙𝑖𝑡𝑟𝑒) =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝐿𝑖𝑣𝑒 𝐶𝑒𝑙𝑙𝑠 𝐶𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑎𝑟𝑔𝑒 𝑐𝑜𝑟𝑛𝑒𝑟 𝑆𝑞𝑢𝑎𝑟𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
× 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 × 10,000 
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Cell Proliferation Studies & Doubling Time Analysis 
  
In order to obtain the cellular growth profile of the U-87 MG cell line, cell proliferation 
studies (increase in the number of cells as a result of growth and division) and doubling time analysis 
(DTA) were performed. For the latter, the population doubling time (PDT) was also assessed and it 
can be defined as the time interval, calculated during the logarithmic phase of growth in which cells 
double in number. PDT can be determined by direct cell counting using a haemocytometer. It is 
important to have in mind that with each subculture the population doubling increases in 
relationship to the slip ratio at which the cells are plated (ATCC, 2012).  
For these studies, cells were plated onto 6-well plates in triplicate at a density of 2.5 x 104 
cells/mL in DMEM. After 6, 24, 48, 72, 96, 120 and 144 hours, cells were collected after typsinization 
and counted using the following formula = h x ln(2)/ ln(c2/c1) for DTA, here c is the number of cells 
at each time of collection and ln is a neperian logarithm (Roth V. 2006 http://www.doubling-
time.com/compute.php).  Cell proliferation graph was performed on Excel 2013 © Microsoft 
Corporation. 
 
Figure 12 – Schematic representation of 
haemocytometer preparation and cell counting. 
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Perturbation studies in vitro 
 
Sulforhodamine B (SRB) Colorimetric Assay 
 
The perturbation effect in the cell system level U-87 MG cell line human glioblastoma 
astrocytoma of two PDK1 inhibitor compounds (G51 and FC100) were evaluated by  the 
Sulforhodamine B (SRB) colorimetric assay (Papazisis et al., 1997). This relies on the uptake of the 
negatively charged pink aminoxanthine dye – SRB, comprising two sulfonic groups (Figure 13) – by 
basic amino acids residues under mild acidic conditions, and dissociate under basic conditions. As 
the binding of SRB is stoichiometric, the amount of dye extracted from stained cells is directly 
proportional to the cell mass (Vichai et al., 2006). 
 
 
 
 
 
 
 
 To perform the assay, cells were seeded at a 5.7 x 104 cells/mL density in 24-well plates, in 
triplicate, being allowed to adhere overnight. After that, cells were washed with PBS, and fresh 
culture medium was added. The test compounds were added at different required concentrations 
in order to achieve a desired final concentration in each well. A control was also prepared, for each 
time-point – 24, 48, 72 and 144 hours (‘𝐶𝑥 ℎ’), where 𝑥 is the time point and ℎ correspond to hours 
– that are treated with PBS, having the same volume of solution with perturbing agent. A control 
named ‘𝐶0’, which just contain cells without any treatment, was performed as well. The plates were 
evaluated at each time-point mentioned above.  
Figure 13 – Sulforhodamine B structure. The molecular 
formula and molecular wight of SRB are C27H29N2NaO7S2 and 
580.6 g/mol, respectively.   From: PubChem Compound 
database, CID 9916275. 
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This type of cell proliferation assay can also be used to determine whether the effect is 
merely cytostatic (decreases cell growth), or cytotoxic (induces cell death) (Houghton et al., 2007). 
Therefore, to do this evaluation, two sets of U-87 MG cells were exposed to the drug under the 
same conditions and for the same period of time. At the end of the exposure period – 72 hours – 
one set of cells was assayed whilst for the other, the medium containing the drug was discarded 
and replaced by fresh culture medium alone. The incubation continued for an additional 72 hours, 
and after this period the plate was assayed. The evaluation of the cytostatic or cytotoxic effect was 
done based as reported in the literature (Houghton et al., 2007): If the drug has only a cytostatic 
effect, the cells will grow and undergo mitosis in the fresh medium but, if they have been killed 
during the initial exposure time, no such increase in number of cells will be observed upon drug 
removal (irreversible effect).  
Regarding the cell fixation and staining step, the cells were fixed by adding 1 mL of cold 1% 
acetic acid/methanol (MeOH), followed by storage at 4 °C. Next day, fixed cell were thaw during 
24h. 500 µL of SRB (0.5 % w/v) was added at each well and they were incubated at 37 °C during 1 
hour. The plates were washed in 1% acetic acid to remove unbound SRB and allowed to dry 
overnight. SRB was solubilised with 1 mL of 10 mM Tris (pH 10) per well, shaken, and after that, the 
supernatant was transferred to 96-well plate and the absorbance was measured at 540 nm.  
To parameterising the perturbation, the % SRB retention was computed by GraphPad Prism 
Software, Version 5.00 for Windows, using One-Way ANOVA method, followed by multiple 
comparison Turkey’s test. Differences were considered statistically significant for p < 0.05; p < 0.01 
and p < 0.001. 
 
Multiparametric Dose-Response Analysis 
 
In this project, the SRB colorimetric assay was used to yield the cellular density as the bases 
for parameterising multiparametric perturbagen dose-response relationships. These relationships 
were performed in computational model approaches available on GraphPad Prism Software, 
Version 5.00 for Windows.  Non-linear fit logistic curves to data on relative growth comprising a 
change in cell number after drug treatment normalized to the change in cell number in a untreated 
control well (C0) were performed. Different dose-response parameters for each individual curve, 
including HS, E0, Einf, GI50 and TGI were estimated. Additionally, it was calculated a parameter AUC 
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representing the area under the relative viability curve, defined as the sum of measured responses 
(relative viability) at all tested concentrations of the drug. Hence, AUC=9 corresponds to an inactive 
compound, whereas smaller AUC values correspond to higher drug activities in inhibiting cell 
proliferation and/or inducing cell death. The parameters IC50 was previously yield by Invitrogen Z’-
LYTE® biochemical assay and the % Inhibition direct to PDK1 – testing at 10 µM – were kindly 
provided by Dr. Simona Rapposelli (Department of Pharmacy, University of Pisa, Italy). 
 
Cell Lysis and Protein Extraction 
 
In order to future characterisations of the effects of PDK1 inhibitors in other system-level 
component, integrating the fate of cellular perturbations multiparametric dose-response 
relationship at specific relevant time-points for each compound, a cell lysis and protein extraction 
procedure was applied (Figure 14). 
Figure 14 – Cell Lysis and protein extraction procedure. Cell lysis is the first step in protein extraction. The 
lysis buffer comprised NaCl, HEPES, MgCl2 and glycerol. The protease inhibition cocktail included leupeptin 
hemisulfate, PMSF, pepstatin A and DTT.   
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Quality Control of the data 
 
As important as get representative samples, choose and execute the technique adequately, 
it is important to calculate and express correctly the results. Hence, the researcher must know the 
mean of the evaluations which perform and be able to manage the uncertainties associated with 
these evaluations. Also, he should know how to detect and eliminate specific errors, as well as to 
discriminate between valid and spurious results (Sores, 2006). Therefore, in this study, a strong 
quality control of the data was performed. After raw data inspection – processed on Excel 2013 © 
Microsoft Corporation and GraphPad Prism Software, Version 5.00 for Windows – the analysis of 
average, amplitude of the sample, coefficient of variation (% CV), standard deviation (SD), standard 
error of the mean (SEM) and Dixon's Q test (90 % of confidence) were calculated. After 
computational model fitting, the goodness of fit was also evaluated by the coefficient of 
determination (R2).  
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Results & Discussion 
 
‘Business as usual’ is no longer an option in drug discovery & development (Csermely et al., 
2013). One of the major health challenges is the desperate need for innovative medicines to treat 
glioblastoma multiforme. Despite this fact, fast, affordable and precisely predictive drug response 
in drug development is still a vision that contrasts sharply with the current state of drug discovery 
(Jiguet et al., 2014). 
In a new-age pharmacology – Quantitative & Systems Pharmacology – computational 
modeling and simulation integrating complex multiparametric readouts of perturbation 
experiments with other associated experimental or clinical data are thought to be critical for better 
understanding both drug effects and disease. Therefore, the present study, and thereby, the results 
presently reported may contribute for the world global data regarding glioblastoma drug discovery 
and development.   
 
Cellular Growth Profile of the U-87 MG cell line 
 
To assess the cellular growth profile of the U-87 MG human cell line, cellular proliferation 
studies and doubling time analysis were carried out. This is a critical step before starting any 
experiments as alterations on the cellular growth can indicate a significant problem within cell line 
and if undetected can have detrimental effects on experimental results.  
The U-87 MG growth curve is represented in Figure 15. The time-point 6 hours was 
performed to evaluate how the cells were adapting to the culture conditions, and as shown, at this 
time they are in Lag Phase, that lasts up to 24 hours. During this period the cells do not divide, even 
showing an insignificant decline on cell density, which states the period of adaptation to the new 
culture conditions. This cell line, shown exponential growth, and so, Logarithmic (Log) growth 
phase, from 24 hours to 72 hours after culturing. During this phase, the division rate systematically 
increase (Figure 15). Regarding the plateau (or stationary) phase, it was reached after 96 hours as 
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the cell population starts to becoming confluent. These results are in accordance with previously 
published growth curves for this same cell line (“Growth Profile for Cell Line: U-87 MG,” n.d.)(Jiguet 
et al., 2014). 
 
 
 
 
 
 
 
 
 
As reported elsewhere (ECACC, 2013), the Log phase is the optimal period to determine the 
population doubling time (PDT), therefore, the double time analysis were performed during this 
phase. And so, the PDT for U-87 MG cell line was 45.6 hours, with a growth rate – number of 
doublings that occur per unit of time – of 1.53 x 10-2. In this study, the value of PDT is slightly higher 
than other values (29 - 34 hours) published in the literature (Ramão et al., 2012; ATCC, 2012; Khoei 
et al., 2011). This may be due to the high number of the cellular subculture (passage #31).   
Figure 15 – Graphical representation of the cell proliferation profile for the U-87 MG cell lina and 
morphological representation of the cells during the logaritmic phase. The cellular proliferation of U-87 MG 
cell line human glioblastoma astrocytoma was assayed, the number of cells counted and cellular density 
calculated at 0, 6 hours time points and then every 24h. Data from an  experiment out of three repetitions is 
shown, representing the cellular density of viable cells. Furthermore, phase-contrast images of cells at 100x 
total amplification are also shown. 
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In vitro Perturbation studies  
 
There is a growing recognition that supporting drug discovery and development integration 
from in vitro to in vivo scales and from preclinical to clinical studies is particular critical. The promise 
of multiscale modeling is to assess the functional impact of molecular perturbations – drug dose 
and exposure, but also genotypic and environmental variations – across changes in scales. This will 
allow across-scale effects assessment or physiological consequences (most often drug action, 
broadly defined, and measured by biomarkers and disease metrics) predictions. Thereby, this type 
of approach should facilitate the focus on treatments and reduce this process cost. The overall 
context of perturbation studies is the new generation quantitative and systems pharmacology. 
In this project, the induced in vitro perturbation on the U-87 MG cell line was evaluated by 
the SRB colorimetric assay, followed parameterisation via multiparametric dose-response analysis.  
 
Sulforhodamine B (SRB) Assay 
 
The SRB method was chosen to assess the cellular perturbation by PDK1 inhibitors 
regarding its advantages over other standard techniques, such as the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) viability test. The SRB assay is sensitive, simple, 
reproducible, more rapid than the formazan-based assays and gives better linearity, a good signal-
to-noise ratio, apart from having a stable end-point that does not require a time-sensitive 
measurement, as does the MMT assay (Houghton et al., 2007). Nonetheless, some compounds can 
directly interfere with MTT reduction, while SRB staining is rarely affected by this type of 
interference (Vichai et al., 2006).  
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The present study measured the perturbation at the cellular system-level of U-87 MG cells 
by a range of dosages of two PDK1 inhibitors, G51 and FC100. The perturbation effect by G51 drug 
can be found on Figure 16. 
 
The most significant perturbation in the cellular system-level was verified after 72 hours of 
incubation with the drug for the higher dose – 40 µM. Also, the cellular system shows a very 
significant perturbation at 20 µM. At 24 and 48 hours there is no significant meaning of system 
perturbation, since no difference of response is observed between the C24h and the other 
treatments at this time-point. However, as the main intent of the systematic perturbation is to 
explore diverse aspects of the signaling response and to maximize the information regarding the 
cell response profiles for model inference, it may be relevant to carry out a detailed analysis of all 
variations of the cellular system occurring as a function of both concentration and time of 
incubation. These results, comprised in Table 10 show that the dosage seems to be more important 
Figure 16 – Perturbation effect of G51 drug at the cellular system-level of U-87 MG cell line. 
The perturbation effect was generated from the percentage of SRB retention, and so, in terms 
of cellular density. The effect of the drug treatment was measured during 72 hours. The vertical 
dotted line at 72 hours represents the drug removal and substitution by new culture medium, 
allowing the evaluation of the reversibility of the drug effect. The results are presented as mean 
values of triplicates and for n=3 (3 independent samples from one independent experiment). 
The bars represent ± SEM. **p < 0.01 vs control, #p < 0.001 vs control, +p < 0.001 vs 72 hours 
treatment. 
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than the duration of treatment for the induction of a significant perturbation:  when comparing the 
lower concentrations at 72 hours to doses in the range 10 µM – 40 µM at the lower time points of 
treatment, there is a higher effect for the latter. Thus, it may suggest that small variations in the 
PDK1 pathway on GBM does not induce an important cell response between 24 and 48 hours, but 
random related events might be perturbed, including biochemical reactions, binding interactions, 
macromolecule complex assembly, transport reactions, conformational changes, and post-
translational modifications. Additionally, for 72 hours of incubation there are no significant 
differences between the C72h and the 2.5 µM, 5 µM and 10 µM doses tested. Further functional 
interactions analysis would help to understand what is happening within this system, but this was 
not the scope of the present study.  
Table 10 – Multiple comparison analysis of the G51 induced perturbation in the cellular 
system-level U-87 MG cell line. 
Turkey’s Multiple 
Comparison Test 
Mean difference of 
perturbation 
Significance 
10 µM 24h vs 2.5 µM 72h -0.3646 p < 0.01 
10 µM 24h vs 5 µM 72h -0.2924 p < 0.05 
20 µM 24h vs 2.5 µM 72h -0.4041 p < 0.001 
20 µM 24h vs 5 µM 72h -0.3320 p < 0.01 
40 µM 24h vs 2.5 µM 72h -0.4334 p < 0.001 
40 µM 24h vs 5 µM 72h -0.3613 p < 0.01 
20 µM 48h vs 2.5 µM 72h -0.4407 p < 0.001 
20 µM 48h vs 5 µM 72h -0.3686 p < 0.01 
40 µM 48h vs 2.5 µM 72h -0.4722 p < 0.001 
40 µM 48h vs 5 µM 72h -0.4001 p < 0.001 
2.5 µM 72h vs 20 µM 72h 0.4317 p < 0.001 
2.5 µM 72h vs 40 µM 72h 0.5006 p < 0.001 
5 µM 72h vs 20 µM 72h 0.3596 p < 0.01 
5 µM 72h vs 40 µM 72h 0.4284 p < 0.001 
10 µM 72h vs 40 µM 72h 0.3124 p < 0.05 
 
Exploring if the induced perturbation leads to a cytotoxic or cytostatic effect, the results 
shown in Figure 16 evidence that as the cells grow and undergo mitosis 3 days after removal of the 
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G51 compound – time point 144 hours – the effect is cytostatic with an extremely significant mean 
for the 20 µM and 40 µM doses. Still analysing that effect, treating the cells with 40 µM dosage, the 
cellular system seems to be more perturbed when compared with 20 µM dosage (C144h vs 20 µM 
144h – 1.647 mean difference; C144h vs 40 µM 144h – 2.114 mean difference; 20 µM 144h vs 40 µM 
144h – 0.4670 mean difference). This highlights again the importance of the dose on the cellular 
system-level perturbation.   
As it is reported, PDK1 pathway has a critical role on both cytostatic and cytotoxic effects 
through  different interactions within the cellular system (Wu et al., 2010; Nesi, 2011b; Nesi, 2011a; 
Velpula et al., 2013). Therefore, it is suggested that the cytostatic effect of this PDK1 inhibitor may 
be associated with the Gap 1 and Synthesis progression (PDK1/Akt/forkhead box transcription 
factors (FOXO) pathway) and cell cycle progression (PDK1/Akt/Raf Murine Sarcoma Viral Oncogene 
Homolog (Raf) kinase pathway) (Wu et al., 2010).    
As to the FC100 drug, its perturbation at the cellular system-level U-87 MG cell line is 
represented in the Figure 17. 
 
 
 
 
 
 
 
Figure 17 - Perturbation effect of FC100 drug at the cellular system-level of U-87 MG cell line.  
The perturbation effect was generated from the percentage of SRB retention, and so, in terms of cellular 
density. The effect of the drug treatment was measured during 72 hours. The vertical dotted line at 72 hours 
represents the drug removal and substitution by new culture medium, allowing the evaluation of the 
reversibility of the drug effect. The results are presented as mean values of triplicates and for n=3 (3 
independent samples from one independent experiment). The bars represent ± SEM. *p < 0.01 vs control, 
#p < 0.001 vs control, +p < 0.001 vs 72 hours treatment. 
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The perturbation of the cellular system U-87 MG by FC100 fails to produce a specific 
cytostatic or cytotoxic effect, irrespective of the concentration tested. In fact, even showing a 
significant difference between cells treated at 72 hours and cells counted 3 days after FC100 
removal (time-point 144 hours), which could indicate a cytostatic effect, there is no significant 
reduction in the percentage of SRB retention of these cells, when compared to the control, for any 
of the time-points considered in the study (24, 48 and 72 hours). However, the higher significant 
mean difference, comparing the time-points 72 and 144 hours was for the dose 40 µM (-1.654), 
whereas, it was not too much different from the effect of the other doses (Table 11).  
Furthermore, there is no evidence of a cytotoxic effect induced by perturbation as no 
significant cell density reduction was verified when compared to C0. However, curiously enough, 
FC100 was found to induce a higher cellular perturbations in the first 24 hours of treatment when 
compared to 48 and 72 hours. Also interesting is the fact that there is no significant perturbation 
differences between the time-points 48 and 72 hours upon treatment with the drug, which might 
indicate that the almost negligible perturbation due to FC100 is induced immediately – shown at 
24 hours – on this cellular system, and then, somehow the U-87 MG cell line turns to be resistant 
to this compound. Inclusively, during the first 24 hours the cell response to FC100 seems to be 
similar for all the dosages tested (Table 11). 
Table 11 - Multiple comparison analysis of the FC100 induced perturbation in the cellular 
system-level U-87 MG cell line. 
Turkey’s Multiple 
Comparison Test 
Mean difference of 
perturbation 
Significance 
2.5 µM 24h vs 2.5 µM 48h -0.6551 p < 0.001 
2.5 µM 24h vs 5 µM 48h -0.6629 p < 0.001 
2.5 µM 24h vs 10 µM 48h -0.6608 p < 0.001 
2.5 µM 24h vs 20 µM 48h -0.7239 p < 0.001 
2.5 µM 24h vs 40 µM 48h -0.5951 p < 0.001 
2.5 µM 24h vs 2.5 µM 72h -0.7807 p < 0.001 
2.5 µM 24h vs 5 µM 72h -0.7722 p < 0.001 
2.5 µM 24h vs 10 µM 72h -0.7988 p < 0.001 
2.5 µM 24h vs 20 µM 72h -0.7377 p < 0.001 
2.5 µM 24h vs 40 µM 72h -0.7068 p < 0.001 
5 µM 24h vs 2.5 µM 48h -0.6672 p < 0.001 
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5 µM 24h vs 5 µM 48h -0.6750 p < 0.001 
5 µM 24h vs 10 µM 48h -0.6729 p < 0.001 
5 µM 24h vs 20 µM 48h -0.7360 p < 0.001 
5 µM 24h vs 40 µM 48h -0.6072 p < 0.001 
5 µM 24h vs 2.5 µM 72h -0.7928 p < 0.001 
5 µM 24h vs 5 µM 72h -0.7843 p < 0.001 
5 µM 24h vs 10 µM 72h -0.8109 p < 0.001 
5 µM 24h vs 20 µM 72h -0.7498 p < 0.001 
5 µM 24h vs 40 µM 72h -0.7189 p < 0.001 
10 µM 24h vs 2.5 µM 48h -0.6200 p < 0.001 
10 µM 24h vs 5 µM 48h -0.6278 p < 0.001 
10 µM 24h vs 10 µM 48h -0.6257 p < 0.001 
10 µM 24h vs 20 µM 48h -0.6888 p < 0.001 
10 µM 24h vs 40 µM 48h -0.5600 p < 0.001 
10 µM 24h vs 2.5 µM 72h -0.7456 p < 0.001 
10 µM 24h vs 5 µM 72h -0.7371 p < 0.001 
10 µM 24h vs 10 µM 72h -0.7637 p < 0.001 
10 µM 24h vs 20 µM 72h -0.7026 p < 0.001 
10 µM 24h vs 40 µM 72h -0.6717 p < 0.001 
20 µM 24h vs 2.5 µM 48h -0.5659 p < 0.001 
20 µM 24h vs 5 µM 48h -0.5737 p < 0.001 
20 µM 24h vs 10 µM 48h -0.5716 p < 0.001 
20 µM 24h vs 20 µM 48h -0.6347 p < 0.001 
20 µM 24h vs 40 µM 48h -0.5059 p < 0.001 
20 µM 24h vs 2.5 µM 72h -0.6914 p < 0.001 
20 µM 24h vs 5 µM 72h -0.6830 p < 0.001 
20 µM 24h vs 10 µM 72h -0.7096 p < 0.001 
20 µM 24h vs 20 µM 72h -0.6484 p < 0.001 
20 µM 24h vs 40 µM 72h -0.6176 p < 0.001 
40 µM 24h vs 2.5 µM 48h -0.6598 p < 0.001 
40 µM 24h vs 5 µM 48h -0.6676 p < 0.001 
40 µM 24h vs 10 µM 48h -0.6654 p < 0.001 
40 µM 24h vs 20 µM 48h -0.7286 p < 0.001 
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40 µM 24h vs 40 µM 48h -0.5998 p < 0.001 
40 µM 24h vs 2.5 µM 72h -0.7853 p < 0.001 
40 µM 24h vs 5 µM 72h -0.7769 p < 0.001 
40 µM 24h vs 10 µM 72h -0.8034 p < 0.001 
40 µM 24h vs 20 µM 72h -0.7423 p < 0.001 
40 µM 24h vs 40 µM 72h -0.7114 p < 0.001 
2.5 µM 72h vs 2.5 µM 144h -1.474 p < 0.001 
5 µM 72h vs 5 µM 144h -1.524 p < 0.001 
10 µM 72h vs 10 µM 144h -1.489 p < 0.001 
20 µM 72h vs 20 µM 144h -1.545 p < 0.001 
40 µM 72h vs 40 µM 144h -1.651 p < 0.001 
 
Taking together the results gathered for FC100 compound with the literature on the protein 
interaction network for GBM, the effect measured for this compound might be related with a quick 
response of the cellular system to the perturbation, possible associated to deoxyribonucleic acid 
(DNA) repair mechanisms, through  PDK1/Akt/tumour protein p53 (TP53) pathway perturbation. 
Further tests at higher dosage levels may provide more definite conclusions on the mechanisms 
involved (Wu et al., 2010). Also, the fact of the perturbation by FC100 drug does not translate in a 
measurable effect on the cellular viability, this does not mean that the other random process were 
not perturbed. Moreover, the hypothetical resistance at the cellular system-level may be due to a 
high metabolism of the compound within the cells. Also, FC100 may not perturb enough the cellular 
system to inhibit random events that promotes cell growth and resistance. For example, it was 
reported recently that EGFR phosphorylation might interact and activate PDK1 in glioblastoma 
multiforme, promoting cancer cell metabolism and tumour progression (Velpula et al., 2013). 
 
Multiparametric Dose-Response Analysis 
 
Patient-to-patient variability in drug response is a primary challenge facing development 
and clinical use of new medicines. Therefore, understanding and parameterising this variability 
early during the drug research process, by analysing a variety of drug parameters responses across 
different types of cell lines representative of the disease model, might reveal and predict the 
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systematic variation in response to cancer drugs in a real therapeutic context (Fallahi-Sichani et al., 
2013). In this project, variation in features other than potency were analysed, namely GI50, TGI, HS, 
Einf, Emax and AUC (Table 12). Additionally, the results provided by the collaborating R&D group from 
the University of Pisa were taking together with those presently gathered for U-87 MG cell line.  
 
Table 12 – Multiparametric dose-response parameters for G51 and FC100 compounds. 
Parameters 
Results System-
Level G51 FC100 
% Inhibition 
PDK1 Direct 
(Z’LYTE® 
Assay) 
92 97 
PDK1 
kinase* 
IC50 (Z’LYTE® 
Assay) 
9.80 x 10-7 M 3.10 x 10-7 M 
PDK1 
kinase* 
Time Points 24h 48h 72h 24h 48h 72h  
GI50 (M) 2.49 x 10-5 1.64 x  10-5 1.38 x 10-5 3.50 x 10-6 1.28 x 10-10 1.98 x 10-5 
U-87 MG 
Cell Line 
TGI (M) 3.70 x 10-5 1.95 x  10-5 1.95 x  10-5 Not Reached 
U-87 MG 
Cell Line 
HS -0.9575 -9.056 -2.924 1.79 ~1.340 ~ -29.32 
U-87 MG 
Cell Line 
Einf -0.6315 -0.1703 -0.3594 1.082 ~0.6732 0.89 
U-87 MG 
Cell Line 
Emax 0.9817 1.41 1.09 3.282 1.456 0.9875 
U-87 MG 
Cell Line 
AUC 2.27 4.41 2.58 13.9 7.28 4.76 
U-87 MG 
Cell Line 
 
An overall analysis of the results, the importance of each calculated parameter to 
characterise the cellular response to the perturbing agent show that the most important difference 
between drugs or between sensitive and resistant cells does not rely on the IC50 only, in accordance 
with previously reported data (Fallahi-Sichani et al., 2013). In fact, sole analysis of the IC50 values, 
*Results from the collaborating R&D group from the University of Pisa (Italy). 
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would lead to the conclusion that FC100 compound would be the most promising compound to 
treat glioblastoma multiforme since its IC50 is much lower than that determined for G51 (3.10 x 10-
7 M vs 9.80 x 10-7 M, respectively). However, other analysed parameters do not corroborate this 
conclusion: the smaller values of AUC for G51 as compared to FC100 reflect a higher drug activity 
for the former, in contrast to the corresponding IC50 values. The higher values of AUC for FC100 
compound, also means that this cell line might be resistant to this drug. In addition, during the 
different time points, the AUC observed for these compounds match well with the results from the 
cellular perturbation shown before. Besides, the results obtained for TGI agree with AUC data, even 
showing that FC100 fails to completely inhibit cell growth up to 40 µM, thus confirming the poor 
activity of this compound towards this cellular system. 
Talking about the steepness – HS – of the dose-response, it can be graphically visualised in 
Figure 18. 
HS is expected to vary in a consistent way with drug class (Fallahi-Sichani et al., 2013). 
However, in this study two drugs of the same class (acting on PDK1) were tested, yielding apparently 
different HS profiles. Although there is no reported a pharmacological explanation for this fact. But, 
as these compounds have difference degrees of affinities for the receptor, other targets than PDK1 
might be influenced in a different way by these drugs.  
The probable suggested acquired resistance of the cellular system to the perturbation by 
FC100 (detected experimentally), may be confirmed by the very low HS values after 72 hours of 
treatment (-29.32) since HS<<1 (shallow dose-response curve) is correlated with high cell-to-cell 
Figure 18 – Multiparametric dose-response curves for G51 and FC100 compounds. Curves were 
generated by fitting logistic curves to data on relative growth comprising a change in cell number after 
drug treatment, normalized to the change in cell number in an untreated control well. The total growth 
inhibition concentration (TGI) is represented. 
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variability in target inhibition compared to drugs for which HS ~1 (Fallahi-Sichani et al., 2013). 
Therefore, this type of response to FC100 means a higher fraction cell killing when compared to the 
G51. In spite of this might be happening for both compounds, the effect in marked for FC100. As a 
result, it indicates that this cellular system contains a subpopulation of cells that were simple 
unaffected at high drug dosages, corroborating the theory of cellular and molecular biology 
heterogeneity of glioblastoma multiforme (Olar et al., 2014; Hofer et al., 2014; Dunn et al., 2012). 
GI50 values are lower for FC100 compound when compared to G51 compound, whereas, the 
first one seems not to induce a high enough perturbation to produce a total growth inhibition of U-
87 MG cell line.  
Regarding the measurement of drug efficacy, for anticancer drugs the high maximal effect 
is obtained when Emax ~ Einf ~ 0, which correspond to death of all of the cells (Fallahi-Sichani et al., 
2013). Analysing our data, G51 compound shows closer values to 0 when compared to FC100. This 
support the HS conclusion about the theory of fractional cell killing, also agreeing with the poor 
drug activity verified for FC100 and its failure to reach TGI values. Additionally, the differences of 
Emax between these pair of drugs confirms that this parameter could be used to distinguish virtually 
drugs as reported (Fallahi-Sichani et al., 2013). As well as, Einf shows different values between this 
pair of drugs, and so, it might could be further evaluated to see if it happen when applying different 
compounds and cell lines. 
Intriguingly and curiously enough, when comparing the drug-likeness score for both drugs, 
FC100 appears to display the ideal properties for a drug, while G51 has undesirable properties. 
Nevertheless, as shown in this study, these computed analyses of physicochemical properties are 
sometimes erroneous, and my exclude compounds with a significant perturbation at cellular level 
and/or having therapeutic effects. It is sometimes reported that these type of predictions based on 
the drug-likeness score might be a hard cut-off of promising agents, and may lead to inaccurate 
conclusions. 
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Conclusions 
 
Twenty first century drug discovery and development welcomes a shift in its scientific 
background since many promising drugs were suddenly followed by disappointment, especially in 
cancer drug discovery and particularly for glioblastoma multiforme, which remains a largely fatal 
disease. Some approaches, such as multidimensional optimization and translational research, are 
helping to increase the success rate at both preclinical and clinical stages, but the high price of 
clinical development requires that even greater efforts are made to ensure that compounds 
entering clinical trials cross the finishing line (Abou-Gharbia et al., 2014). 
In this dissertation many strategies were described to improve the drug discovery and 
development process, and some of them were applied to this masters’ project. For instance, this 
study brought together several academic institutions (from Portugal and Italy) showing that such 
interdisciplinary collaborations are desirable and beneficial to this type of research activity. 
 With a view to analyse the effect of the PDK1 inhibitors under investigation, a novel 
concept – parameterisation of dose-response perturbations – was successfully applied. This 
approach is based on Quantitative and Systems Pharmacology, which intends to improve the drug 
discovery and development process by promoting a more detailed characterization of both the 
disease and the drug response, integrating these effects at different levels. 
Within this type of strategy, it was possible to conclude that the perturbation induced by 
the G51 – a PDK1 inhibitor – has a cytostatic effect against the human cellular system U-87 MG, 
whereas the FC100 compound shows no evident effect on these cells and cellular resistance might 
occur. In addition, the importance of the multiparametric analysis other than potency – IC50 – was 
proven: It is obviously an important goal to reduce IC50 values, but this may not be enough for an 
agent to be considered a promising drug and it cannot provide sufficient information to properly 
understand the variability of cellular responses to a drugs. Hence, other parameters, such as 
steepening the dose-response relationships, increase the maximum effect and the activity of the 
drug might important parameters to focus when developing new drugs.  
A limitation of this study is the reduced reported similar studies, as so far only one 
analogous work has been performed, to the author’s knowledge in this specific area of QSP. On 
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other hand, it is a proof of the high level of innovation of the present investigation as it is the first 
of its kind to be carried out in Portugal, applying this innovative concept to parameterise the 
perturbation induced by PDK1 inhibitors at the cellular system-level U-87 MG.    
In further studies, it would be interesting understand the processes associated to the 
perturbation profile induced by these PDK1 inhibitors on the U-87 MG cellular system, particularly 
the functional mechanisms related to the cellular resistance proposed for the FC100 compound. 
Furthermore, it would be useful to translating this results for other system-levels in order to 
understand the effects of the perturbation verified.        
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